VivoSeq
Infectious Disease

Herpes Zoster

60

Pipeline Programs

37

Active Trials

36

Companies Involved

Herpes Zoster is a moderately active landscape with 60 programs across 36 companies. The most active players are Immorna Biotherapeutics, Inc., Suzhou Abogen Biosciences Co., Ltd., Centrexion Therapeutics. 13 therapies are approved with 12 more in late-stage development.

Pipeline Metrics

Competitive Density

65/100

Pipeline Velocity

42/100

Mech. Concentration

50/100

Completion Rate

93/100

Attrition Rate

4/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Modality Breakdown

74programs
Small molecule4358%
Vaccine3142%

Modality classified for 100% of 93 pipeline programs.

Trial Status

102

clinical trials

Completed54 · 53%
Recruiting21 · 21%
Active, not recruiting8 · 8%
Not yet recruiting8 · 8%
Unknown status7 · 7%
Terminated4 · 4%

Trial Activity

102 trials

Safety of the Herpes Zoster Subunit Vaccine in Lupus
Recruiting·NNYU Langone Health·Phase 4·NCT05559671·224 enrolled
Page 1 of 7

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)